Recently, Sinovac BiotechSinovac Biotech Co., Ltd. (hereinafter referred to as " Sinovac Biotech")(Stock code 688136.SH) and Shanghai PharmaceuticalsChangzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory"), a subsidiary of the Group, held a strategic cooperation signing ceremony and an exclusive licensing agreement for two products, ticagrelor tablets and rosuvastatin calcium tablets, in several European countries. Leveraging Sinovac Biotech 's mature overseas commercialization network and Changzhou Pharmaceutical Factory's high-quality product R&D and manufacturing capabilities, the two parties will join hands to expand into the European market, bringing domestically produced cardiovascular drugs to more patients.

Enriching the European product line and continuously cultivating the major market

It is understood that both products launched through this collaboration have been approved in China and the United States and are currently undergoing registration applications in several European countries. The cooperation covers markets including Germany, Spain, the Netherlands, Italy, and France. Ticagrelor tablets have already been registered and approved in Italy and France, while rosuvastatin calcium tablets have been approved in the Netherlands.

Ticagrelor tablets and rosuvastatin calcium tablets are both cardiovascular disease treatments with significant clinical value and broad market prospects. Ticagrelor tablets, when administered in combination with acetylsalicylic acid (ASA), are suitable for the prevention of acute coronary syndrome .Patients with atherosclerotic thrombotic events (ACS) or those with a history of myocardial infarction (MI) and at high risk of atherosclerotic thrombotic events.

According to Business Research, the global ACS market size is projected to be $10.07 billion in 2026 and expand to $14.03 billion by 2035, with a CAGR of 3.7% from 2026 to 2035. According to MIDAS data, global sales of ticagrelor tablets reached $2.03 billion in 2024, with $347 million coming from Europe.

Rosuvastatin calcium tablets are a third-generation statin lipid-lowering drug, mainly used for primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) whose blood lipid abnormalities cannot be adequately controlled by diet and other non-pharmacological treatments (such as exercise and weight loss), as well as for the prevention of cardiovascular diseases.

According to Persistence's forecast, the global statin market is projected to reach $16.6 billion in 2025 and $20.6 billion by 2032, representing a CAGR of 3.1%. This growth is primarily driven by the increasing incidence of cardiovascular disease, heightened awareness of cholesterol management, and the demand for effective lipid-lowering therapies due to an aging population. MIDAS data shows that global sales of rosuvastatin calcium tablets reached $3.31 billion in 2024, with $706 million coming from Europe.

The European market has been a key focus for Sinovac Biotech in recent years. Leveraging the approval of its blockbuster product, albumin-bound paclitaxel, from the European Commission, Sinovac has rapidly established a foothold in the European pharmaceutical market. According to Frost & Sullivan data, by the first half of 2025, Sinovac's albumin-bound paclitaxel exports will account for 47.7% of China's total exports of similar products. This overseas commercialization collaboration with Changzhou Pharmaceutical Factory for two products will help enrich the company's product portfolio in the European market and further enhance its market competitiveness.

A powerful alliance to embark on a new journey for cardiovascular drugs overseas.

On the same day, Chen Ye, General Manager of Changzhou Pharmaceutical Factory, and Shao Ke, Deputy General Manager of Sinovac Biotech, attended the signing ceremony and delivered speeches. Shao Ke stated that this strategic cooperation with Changzhou Pharmaceutical Factory is an important step for Sinovac Biotech in deepening its presence in the European market and expanding its global business. In the future, the company will fully leverage its advantages in overseas registration and marketing channels to rapidly introduce two high-quality products into the European market, achieving mutual value creation and synergistic development.

Chen Ye, General Manager of Changzhou Pharmaceutical Factory, stated that Changzhou Pharmaceutical Factory has been deeply involved in the pharmaceutical field for many years, accumulating profound strength in formulation production and quality control. The ticagrelor tablets and rosuvastatin calcium tablets, which are being exported through this collaboration, are both essential cardiovascular drugs in clinical practice, and their quality and efficacy have been fully validated. He believes that through close cooperation between the two parties, the penetration of these two products into overseas markets can be accelerated, enhancing the global influence of domestically produced pharmaceutical products and achieving a dual improvement in social and economic benefits.

In recent years, Sinovac Biotech has continued to deepen its "innovation + internationalization" dual-drive strategy. On the one hand, it has opened up cooperation to introduce a number of high-quality, clinically valuable products, forming a pharmaceutical export platform with its own characteristics. On the other hand, it has increased R&D investment, focusing on the fields of oncology and autoimmune diseases to develop multiple global innovative drug pipelines.Pipeline is committed to becoming an innovative, international biopharmaceutical company serving patients worldwide.

About Changzhou Pharmaceutical Factory Co., Ltd.

Changzhou Pharmaceutical Factory Co., Ltd. is one of the core industrial enterprises of Shanghai Pharmaceuticals Group Co., Ltd., and is a chemical raw material manufacturer.A comprehensive pharmaceutical company with a focus on both pharmaceutical and chemical drug formulations, and with all-round development in science, industry, and trade . The company produces more than fifty kinds of active pharmaceutical ingredients annually.It offers over 150 product specifications, including small-volume injections, tablets, and capsules. Product areas cover cardiovascular and cerebrovascular drugs, antipyretic analgesics, antibiotics, and vitamins.Health productsThe company produces six major series of drugs, including anti-tumor drugs. Its products are exported to over 50 countries and regions, including the United States, Germany, France, Brazil, India, Singapore, and Japan. It is the preferred raw material supplier for the world's top ten largest generic drug manufacturers. In November 2007, the company passed EU GMP certification, becoming the second company in Jiangsu Province and the seventh nationwide to achieve this certification. It has received honors such as "China Famous Trademark" and "National Green Factory," and has repeatedly been recognized as a provincial-level "High-tech Enterprise" and a " Specialized, Refined, and Innovative Enterprise of Jiangsu Province."It has received honors such as "Little Giant Enterprise" and "Changzhou Five-Star Industrial Enterprise". It has also been successfully selected as a national "Demonstration Enterprise for Pharmaceutical Quality and Integrity Construction" and a "Jiangsu Province Pharmaceutical Industry Integrity Enterprise".

https://finance.eastmoney.com/a/202603203678893029.html